Holen Sie sich die Stockscreener-App
11.11
1.77%
-0.2156
Phathom Pharmaceuticals Inc Aktie (PHAT) Neueste Nachrichten
How (PHAT) Movements Inform Risk Allocation Models - Stock Traders Daily
PHAT SEC FilingsPhathom Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
Hear Phathom at three upcoming healthcare investor conferences - Stock Titan
Phathom Pharmaceuticals to Participate in Upcoming Investor Conferences - The Manila Times
Phathom (NASDAQ: PHAT) director gains shares via options and RSUs - Stock Titan
Phathom (PHAT) director James Topper receives 24,122 RSUs in equity grant - Stock Titan
Director Mark Stenhouse awarded 24,122 RSUs at Phathom (PHAT) - Stock Titan
Director at Phathom Pharmaceuticals (PHAT) granted 24,122 RSUs - Stock Titan
Director Michael Cola (PHAT) receives 24,122 RSUs in equity award grant - Stock Titan
Director Frank Karbe receives 24,122 RSUs at Phathom (NASDAQ: PHAT) under board compensation plan - Stock Titan
Director Theodore Schroeder (PHAT) receives 24,122 RSU award under non-employee plan - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) reports 2026 annual meeting vote outcomes - Stock Titan
Phathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual Meeting - The Manila Times
Stomach drug vonoprazan draws 28 independent studies at DDW 2026 - Stock Titan
Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28 - Moomoo
Analyst Reiterates Buy on Phathom as Voquezna Strategy Advances; $28 Price Target Maintained - TipRanks
TradingKey - TradingKey
Number of shareholders of Phathom Pharmaceuticals, Inc. – NASDAQ:PHAT - TradingView
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat
Phathom Pharmaceuticals CEO drives new momentum after DDW2026 to advance GI patient care - Traders Union
Phathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability Timeline - Yahoo Finance
Phathom outlines $320M-$345M 2026 revenue as it targets operating profitability by Q3 - MSN
How Phathom Pharmaceuticals Inc. (PHAT) Affects Rotational Strategy Timing - Stock Traders Daily
147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc. - MarketBeat
How The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity Risks - Yahoo Finance
Analysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX) - The Globe and Mail
Phathom Pharmaceuticals Signals Strong Growth on Earnings Call - The Globe and Mail
Earnings call transcript: Phathom Pharmaceuticals beats Q1 2026 EPS expectations - Investing.com Australia
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5%Should You Buy? - MarketBeat
A Quick Look at Today's Ratings for Phathom Pharmaceuticals(PHAT.US), With a Forecast Between $25 to $28 - Moomoo
Phathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Q1 2026 Earnings Call Transcript - Insider Monkey
Phathom Pharmaceuticals announces DDW2026 booth and team participation in Chicago - Traders Union
Phathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual Meeting - The Manila Times
GERD drug VOQUEZNA gets 3 posters and a May 4 presentation at DDW - Stock Titan
Phathom Pharmaceuticals Inc (PHAT) Q1 2026 Earnings Call Highlig - GuruFocus
Phathom Pharmaceuticals Reports Q1 2026 Results: VOQUEZNA Prescriptions Surge, Revenue Doubles, Operating Profitability Expected in Q3 - Minichart
Phathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPS - MarketBeat
Phathom Pharmaceuticals, Inc. 2026 Q1ResultsEarnings Call Presentation (NASDAQ:PHAT) 2026-04-30 - Seeking Alpha
Phathom Pharmaceuticals Q1 Earnings Call Highlights - MarketBeat
Phathom Pharmaceuticals, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Phathom Pharmaceuticals, Inc. (PHAT) reports Q1 loss, tops revenue estimates - MSN
Phathom (PHAT) Q1 2026 Earnings Transcript - The Globe and Mail
Phathom Pharmaceuticals Q1 2026 Earnings Call Transcript - MarketBeat
Phathom Pharmaceuticals Releases Q1 2026 Financial Results - AlphaStreet
Phathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings Miss - MarketBeat
Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026 By Investing.com - Investing.com South Africa
Is Phathom Pharmaceuticals (PHAT) Fairly Valued After Q1 2026 Ea - GuruFocus
Earnings call transcript: Phathom Pharmaceuticals beats EPS expectations in Q1 2026 - Investing.com
Phathom Pharmaceuticals Reports Q1 2026 Results: Full Earnings Call Transcript - Benzinga
Phathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Q1 2026 Phathom Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Reports Q1 Product Revenue $58.3M, vs. FactSet Est of $55.9M - marketscreener.com
Earnings Flash (PHAT) Phathom Pharmaceuticals, Inc. Posts Q1 Adjusted Loss $0.18 per Share, vs. FactSet Est of $-0.21 - marketscreener.com
Phathom Pharmaceuticals Q1 2026 earnings preview - MSN
8-K: Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Updatemoomoo - Moomoo
Phathom Pharmaceuticals | 10-Q: Q1 2026 Earnings Report - Moomoo
Phathom Pharmaceuticals reports Q1 2026 revenue $58.3M, narrows net loss to $30.4M - TradingView
Phathom Pharmaceuticals Q1 revenue more than doubles, beats estimates - TradingView
1.35M VOQUEZNA prescriptions filled; Phathom expects Q3 operating profitability - Stock Titan
VOQUEZNA growth moves Phathom (NASDAQ: PHAT) closer to profitability - Stock Titan
Phathom Pharmaceuticals (NASDAQ: PHAT) doubles Q1 2026 revenue, cuts loss - Stock Titan
Phathom Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update - ChartMill
2.25%
0.46%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):